Clinical trial
Safety and Effectiveness of a Vaccine for Prostate Cancer That Uses Each…
NCT00289341 · Rockefeller University, Other · Completed
Key facts
| NCT number | NCT00289341 |
|---|---|
| Title | Safety and Effectiveness of a Vaccine for Prostate Cancer That Uses Each Patients' Own Immune Cells. |
| Official title | A Phase I/II Study of Autologous Dendritic Cells Pulsed With Apoptotic Tumor Cells (DC/LNCaP) Administered Subcutaneously to Prostate Cancer Patients. |
| Lead sponsor | Rockefeller University, Other |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Biological |
| Interventions | vaccine vehicle only, DC/LNCaP |
| Enrollment | 24 |
| Start date | Mar 1, 2002 |
| Primary completion | Nov 1, 2008 |
| Completion | Nov 1, 2008 |
| First posted | Feb 9, 2006 |
| Last update posted | Jan 18, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: